Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CING
STRONG SELLCingulate Inc. · Healthcare · United States · $67M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Cingulate Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release drug delivery platform to develop improved treatments for ADHD and other neuropsychiatric disorders. The company's competitive advantage lies in its ability to deliver multiple, precisely timed doses of active ingredients from a single tablet, addressing unmet clinical needs. Cingulate operates as a niche biotechnology player focused on optimizing established therapeutic molecules.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 2.9M | 20.0M | — |
| EPS | -1.31 | -2.25 | -1.15 | -3.10 | — | -4.39 | -2.30 | -0.74 | — |
| Shares | 13.5M | 13.5M | 13.5M | 7.3M | -46.2% | — | — | — | — |
| Debt | 5.9M | 3.5M | 5.1M | 8.8M | 14.4% | 7.4M | — | — | — |
| Equity | 3.9M | -6.9M | 7.5M | 2.5M | -13.5% | — | — | — | — |
| Op CF | -15.9M | -15.0M | -18.5M | -17.2M | — | -19.5M | — | — | — |
| Inv CF | -0.2M | -0.2M | -0.2M | -0.2M | — | — | — | — | — |
| Fin CF | 4.9M | 10.0M | 30.8M | 16.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CING are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CING | Cingulate Inc.(you) | $67M | 13 | STRONG SELL |
| ACRV | Acrivon Therapeutics, Inc. | $72M | 14 | STRONG SELL |
| 4875.T | MediciNova, Inc. | $62M | 15 | STRONG SELL |
| FLNA | Filana Therapeutics, Inc. | $58M | 9 | STRONG SELL |
| CNTX | Context Therapeutics Inc. | $53M | 10 | STRONG SELL |
| DWTX | Dogwood Therapeutics, Inc. | $55M | 9 | STRONG SELL |
| TIL | Instil Bio, Inc. | $50M | 10 | STRONG SELL |
| GOSS | Gossamer Bio, Inc. | $77M | 7 | STRONG SELL |
| ANIX | Anixa Biosciences, Inc. | $95M | 14 | STRONG SELL |
| HRTX | Heron Therapeutics, Inc. | $81M | 8 | STRONG SELL |
Peer medians: ROE -21.2% · P/E 27.1x · Gross margin 44.5%